We observed that TWEAK treatment increased nuclear E2F4 and E2F5 protein levels in glioma cells, with E2F4 having greater nuclear translocation in BT25 cells and E2F5 in BT114 cells (Figure 4A). This evidence concerns the gene E2F4 and central nervous system cancer.